Skip to content 
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. more
| Time Frame | LLY | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -2.47% | 1.75% | 1.05% |
| 1-Month Return | -5.3% | -3.02% | -2.74% |
| 3-Month Return | 15.75% | 1.93% | 4.56% |
| 6-Month Return | 24.04% | 11.24% | 20.31% |
| 1-Year Return | 92.6% | 6.02% | 24.48% |
| 3-Year Return | 305.37% | 19.75% | 26.81% |
| 5-Year Return | 570% | 76.04% | 88.12% |
| 10-Year Return | 1437.89% | 186.26% | 224.44% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 22.32B | 24.54B | 28.32B | 28.54B | 34.12B | [{"date":"2019-12-31","value":65.41,"profit":true},{"date":"2020-12-31","value":71.91,"profit":true},{"date":"2021-12-31","value":82.99,"profit":true},{"date":"2022-12-31","value":83.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Cost of Revenue | 4.72B | 5.48B | 7.31B | 6.63B | 6.58B | [{"date":"2019-12-31","value":64.56,"profit":true},{"date":"2020-12-31","value":74.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.66,"profit":true},{"date":"2023-12-31","value":89.92,"profit":true}] |
| Gross Profit | 17.60B | 19.06B | 21.01B | 21.91B | 27.55B | [{"date":"2019-12-31","value":63.88,"profit":true},{"date":"2020-12-31","value":69.18,"profit":true},{"date":"2021-12-31","value":76.25,"profit":true},{"date":"2022-12-31","value":79.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Gross Margin | 78.85% | 77.66% | 74.18% | 76.77% | 80.73% | [{"date":"2019-12-31","value":97.67,"profit":true},{"date":"2020-12-31","value":96.19,"profit":true},{"date":"2021-12-31","value":91.88,"profit":true},{"date":"2022-12-31","value":95.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Expenses | 11.81B | 12.21B | 13.46B | 13.63B | 17.22B | [{"date":"2019-12-31","value":68.57,"profit":true},{"date":"2020-12-31","value":70.88,"profit":true},{"date":"2021-12-31","value":78.14,"profit":true},{"date":"2022-12-31","value":79.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Income | 4.97B | 6.06B | 6.36B | 7.13B | 10.33B | [{"date":"2019-12-31","value":48.18,"profit":true},{"date":"2020-12-31","value":58.67,"profit":true},{"date":"2021-12-31","value":61.57,"profit":true},{"date":"2022-12-31","value":69.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (28.60M) | 845.30M | (516.00M) | (589.70M) | (4.08B) | [{"date":"2019-12-31","value":-3.38,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-61.04,"profit":false},{"date":"2022-12-31","value":-69.76,"profit":false},{"date":"2023-12-31","value":-483.04,"profit":false}] |
| Pre-Tax Income | 5.27B | 7.23B | 6.16B | 6.81B | 6.55B | [{"date":"2019-12-31","value":72.84,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":85.14,"profit":true},{"date":"2022-12-31","value":94.14,"profit":true},{"date":"2023-12-31","value":90.66,"profit":true}] |
| Income Taxes | 628.00M | 1.04B | 573.80M | 561.60M | 1.31B | [{"date":"2019-12-31","value":47.79,"profit":true},{"date":"2020-12-31","value":78.85,"profit":true},{"date":"2021-12-31","value":43.66,"profit":true},{"date":"2022-12-31","value":42.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Income After Taxes | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
| Income From Continuous Operations | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
| Income From Discontinued Operations | 3.68B | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 4.64B | 6.19B | 5.58B | 6.24B | 5.24B | [{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}] |
| EPS (Diluted) | 6.04 | 7.93 | 8.17 | 8.09 | 6.32 | [{"date":"2019-12-31","value":73.93,"profit":true},{"date":"2020-12-31","value":97.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":77.36,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| LLY | |
|---|---|
| Cash Ratio | 0.11 |
| Current Ratio | 0.94 |
| Quick Ratio | 0.73 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LLY | |
|---|---|
| ROA (LTM) | 11.88% |
| ROE (LTM) | 48.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LLY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.83 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 5.94 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LLY | |
|---|---|
| Trailing PE | 128.13 |
| Forward PE | 60.24 |
| P/S (TTM) | 20.94 |
| P/B | 66.34 |
| Price/FCF | NM |
| EV/R | 21.60 |
| EV/Ebitda | 86.01 |
| PEG | NM |
The majority of leading global indices reached new highs in 2024, fueled by loose financial conditions and burgeoning enthusiasm for artificial intelligence ( AI ). In the U.S., this rally pushed the S&P 500 to fresh highs. And unwavering investor optimism and the prospect of stocks joining the trillion-dollar club maintained the surge. Historically, the markets prefer challenging complacency among investors. This lesson seems particularly important today. Initially, market sentiment was buoyed by expectations of multiple interest rate cuts by the Federal Reserve, with predictions of up to seven reductions by January 2025. However, contrary to these expectations, recent data indicates stronger-than-anticipated economic growth and rising inflation. Yet, investors remain undeterred. They are pivoting to a narrative of a reaccelerating economy bolstering the markets. Despite this optimism, there are signs of caution. Analysts have been revising earnings estimates downward for this year and next, while the stock market’s strength is concentrated in a select group of mega-cap stocks.
Lilly recently announced news that could solve a big problem.
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment. The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity spending is expected to increase at a compound annual rate as high as 27% between 2024 and 2028. There’s lots of room left for future treatments to enter the world of weight loss drug stocks. Altimmune (ALT) Source: Vladimka production / Shutterstock Altimmune (NASDAQ: ALT ) is one of the most promising weight loss drug stocks for a very simple, powerful reason. Clinical weight loss is associated with a decrease in fat mass and muscle mass. The more muscle mass that can be retained, the better.
Many investors look to analysts’ expectations to guide their movements each quarter. Typically, those investors can reasonably use estimates as a reference. However, some stocks rise above and beyond those expectations with breakthrough products, exciting partnerships/deals and incredible quarterly performances. Stocks with such potential give investors a golden opportunity to buy at a lower price but enjoy considerable returns after a company’s performance blows away any and all estimates. We have gathered the three stocks to buy, destined for tremendous growth and most likely to beat analyst expectations this year. Let’s learn more about each company’s exciting products set to be released this year, propelling these stocks’ 2024 performances to skyrocket. Viking Therapeutics (VKTX) Source: ra2 studio/Shutterstock Viking Therapeutics (NASDAQ: VKTX ) is capitalizing on one of the hottest trends right now to propel its stock higher. The company’s new obesity drug, VK2735, has made great strides, passing clinical trials and getting closer and closer to approval and release.
Indianapolis: Eli Lilly and Company and Nexus Pharmaceuticals , LLC have … sterile manufacturer in the pharmaceutical industry. The acquisition … manufacture specialty and generic drugs that are easier … : CDSCO Panel Approves Eli Lilly ''s protocol amendment …
There’s plenty out there that could potentially drive a broad market pullback, but there are also plenty of individual stocks due for a pullback. Irrespective how the market performs from here, these types of stocks may be in for considerable declines in price. Several of the stocks that have thus far this year been top-performers fit into this category. While in some cases, big run-ups have been justified, there are plenty that can be deemed as situations where shares have moved up “too far, too fast.” Admittedly, just because investors have gone overboard about a certain stock, doesn’t mean the market will soon come to its senses. Just ask the bears who have lost billions betting against Carvana (NYSE: CVNA ). However, don’t assume high-flier resiliency is universal. In the case of the following seven stocks due for a pullback, there are identifiable factors that strongly suggest a reversal lies ahead for each one. Cava Group (CAVA) Source: Bruce VanLoon / Shutterstock.com Cava Group (NYSE: CAVA ) bolted higher after its June 2023 IPO , but slid lower throughout the rest of last year.
For pharmaceutical company Eli Lilly (NYSE:LLY), it’s been doing some great things of late with a string of drugs. And, seeing that supply is getti…
Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the […] The post Eli Lilly acquires new injectable medicine manufacturing plant appeared first on Drug Delivery Business .
Eli Lilly and Company (LLY) share price today is $732.2
Yes, Indians can buy shares of Eli Lilly and Company (LLY) on Vested. To buy Eli Lilly and Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LLY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Eli Lilly and Company (LLY) via the Vested app. You can start investing in Eli Lilly and Company (LLY) with a minimum investment of $1.
You can invest in shares of Eli Lilly and Company (LLY) via Vested in three simple steps:
The 52-week high price of Eli Lilly and Company (LLY) is $800.78. The 52-week low price of Eli Lilly and Company (LLY) is $377.61.
The price-to-earnings (P/E) ratio of Eli Lilly and Company (LLY) is 126.74
The price-to-book (P/B) ratio of Eli Lilly and Company (LLY) is 66.34
The dividend yield of Eli Lilly and Company (LLY) is 0.7%
The market capitalization of Eli Lilly and Company (LLY) is $698.47B
The stock symbol (or ticker) of Eli Lilly and Company is LLY
Link copied 
